NCT05911841

A Study of LY3454738 in the Treatment of Adult Participants With Moderate-to-Severe Atopic Dermatitis

A Phase 2, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled, 52 Week Study to Evaluate the Efficacy and Safety of LY3454738 in the Treatment of Adult Patients With Moderate-to-Severe Atopic Dermatitis

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 234 (actual)
• Sponsor: Eli Lilly and Company · Industry
• Sex: All
• Age: 18 Years – 70 Years
• Healthy volunteers: Not accepted

Summary

The main purpose of this study is to describe the efficacy and safety of LY3454738 in adult participants with moderate-to-severe atopic dermatitis (AD).

Conditions

• Atopic Dermatitis

Interventions

Type	Name	Description
DRUG	LY3454738	Administered SC
DRUG	Placebo	Administered SC

Timeline

• Start date: 2023-06-21
• Primary completion: 2024-10-10
• Completion: 2025-03-14
• First posted: 2023-06-22
• Last updated: 2025-12-02
• Results posted: 2025-12-02

Locations

66 sites across 9 countries: United States, Canada, China, Hungary, Japan, Mexico, Poland, South Korea, Taiwan

Regulatory

• FDA-regulated drug study